Results 121 to 130 of about 2,408 (179)
Some of the next articles are maybe not open access.
What’s going on in LDL apheresis
Transfusion and Apheresis Science, 2007(1) immunoadsorption (IMA), which consists of selective removal of LDL from plasma using polyclonal sheep anti-LDL antibodies; (2) direct adsorption of lipoprotein from whole blood, hemoperfusion using non-hemolytic polyacrylate-coated polyacrilamide gel (DALI), with the advantage of a shorter procedure time; (3) presently available, a new system of ...
Daniela, Onofrillo, Patrizia, Accorsi
openaire +2 more sources
Release of microparticles in LDL apheresis
Transfusion and Apheresis Science, 2001Particle contamination of blood always takes place in extracorporeal systems and few studies have been conducted to evaluate potential risks. Particle concentration was measured in the efferent blood line on original equipment for two established LDL elimination procedures (DALI) (Fresenius) and Liposorber (Kaneka).
G B, Matic +5 more
openaire +2 more sources
Transfusion and Apheresis Science, 2007
LDL apheresis is a technology used worldwide for the treatment of refractory familial hypercholesterolemia [1]. In Italy, this extracorporeal treatment has been applied for the last 20 years, firstly by using plasma exchange and cascade filtration and by the end of the 1980’s introducing the first selective systems for LDL apheresis on a routine basis.
openaire +2 more sources
LDL apheresis is a technology used worldwide for the treatment of refractory familial hypercholesterolemia [1]. In Italy, this extracorporeal treatment has been applied for the last 20 years, firstly by using plasma exchange and cascade filtration and by the end of the 1980’s introducing the first selective systems for LDL apheresis on a routine basis.
openaire +2 more sources
Ldl-Apheresis on Affine Haemosorbents
Biomaterials, Artificial Cells and Artificial Organs, 1990There were synthesized new hemosorbents for selective removal of LDL, based on macroporous silica, immobilised by heparine (sorbent 1) and chytozane-sulphate (sorbent 2). Experimental data showed satisfactory hemo- and biocompatibility of the new sorbents. No significant alterations in biochemical parameters were observed.
, Lopukhin YuM +4 more
openaire +2 more sources
Current Treatment Options in Cardiovascular Medicine, 2006
Low-density lipoprotein (LDL)-apheresis is an effective means for acutely lowering plasma cholesterol (LDL reduction > 60%) and reducing cardiovascular events in patients with uncontrolled hypercholesterolemia who are genetically predisposed or resistant to standard therapy.
openaire +2 more sources
Low-density lipoprotein (LDL)-apheresis is an effective means for acutely lowering plasma cholesterol (LDL reduction > 60%) and reducing cardiovascular events in patients with uncontrolled hypercholesterolemia who are genetically predisposed or resistant to standard therapy.
openaire +2 more sources
Pleiotropic effects of LDL apheresis
Atherosclerosis Supplements, 2009LDL apheresis (LA), a technique employed to remove atherogenic lipoproteins, has been shown to exert a protective function on the vessel walls. This effect can be attributed to pleiotropic mechanisms that safeguard against endothelial dysfunction by reducing the concentrations of pro-inflammatory and pro-coagulation markers.
Alfonso, Ramunni +3 more
openaire +2 more sources
Treatment of Severe Hypercolesterolaemia by LDL-Apheresis
Biomaterials, Artificial Cells and Immobilization Biotechnology, 1991The most severe forms of hypercholesterolaemia scarcely respond to diet and conventional drugs administration and need, therefore, alternative treatments. Terapeutic Plasma Exchange demonstrated an improved survival of subjects with Familial Hypercholesterolaemia (FH) in spite of its limitations.
SCARPATO, NICOLA +6 more
openaire +3 more sources
LDL Apheresis in Atherosclerotic Disease with Hyperlipidemia
ASAIO Journal, 1992Low density lipoprotein (LDL) apheresis was carried out in 28 atherosclerotic patients with clinical signs of poor peripheral circulation and abnormally high LDL levels. The LDL apheresis using extracorporeal adsorption with a dextran sulfate cellulose column (Liposorber, Kaneka, Japan) was done 10 times over 3 months.
S, Naganuma, T, Agishi, K, Ota
openaire +2 more sources
Comparison of different LDL apheresis methods
Expert Review of Cardiovascular Therapy, 2008This article presents the generally accepted indications for LDL apheresis treatment. The available LDL apheresis methods differ with respect to acute relative reductions of LDL cholesterol; mean values after the LDL apheresis treatments are not different. Serum triglycerides, HDL-cholesterol, and lipoprotein(a) are also acutely reduced.
Ulrich, Julius +5 more
openaire +2 more sources
LDL Apheresis and Inflammation – Implications for Atherosclerosis
Scandinavian Journal of Immunology, 2012AbstractLow‐density lipoprotein (LDL) apheresis is an extracorporeal treatment modality used in high‐risk patients when LDL cholesterol levels cannot be reduced adequately with medication. The treatment is highly effective, but could be affected by potential unwanted effects on pro‐ and anti‐inflammatory biomarkers.
A, Hovland +2 more
openaire +2 more sources